The failure of two Phase III trials combining Fovista (pegpleranib) with Lucentis (ranibizumab) will likely bring to an end the debate over whether efficacy of vascular endothelial growth factor (VEGF) inhibition in the treatment of wet age-related macular degeneration (AMD) can be enhanced by the simultaneous inhibition of platelet-derived growth factor (PDGF).
The key takeaway for investors of that news – aside from the disaster it implies for Fovista developer...







![Spotlight On RDCs, AOCs As Leading Novel Bioconjugates[Updated]](https://web.insights.norstella-labs.com/resizer/v2/3M7ZAWZOBNK7NG4A4WDOIFG6DU.jpg?smart=true&auth=392a1fdb3cfacb29445720c412410e598dbcc5f90f14857652cd498bd0faa0fb&width=400&height=225)